Decoding the epitranscriptome: a new frontier for cancer therapy and drug resistance.

IF 8.2 2区生物学 Q1 CELL BIOLOGY

Cell Communication and Signaling Pub Date : 2024-10-21 DOI:10.1186/s12964-024-01854-w

Lu Tang, Hua Tian, Qi Min, Huili You, Mengshuang Yin, Liqiong Yang, Yueshui Zhao, Xu Wu, Mingxing Li, Fukuan Du, Yu Chen, Shuai Deng, Xiaobing Li, Meijuan Chen, Li Gu, Yuhong Sun, Zhangang Xiao, Wanping Li, Jing Shen

{"title":"Decoding the epitranscriptome: a new frontier for cancer therapy and drug resistance.","authors":"Lu Tang, Hua Tian, Qi Min, Huili You, Mengshuang Yin, Liqiong Yang, Yueshui Zhao, Xu Wu, Mingxing Li, Fukuan Du, Yu Chen, Shuai Deng, Xiaobing Li, Meijuan Chen, Li Gu, Yuhong Sun, Zhangang Xiao, Wanping Li, Jing Shen","doi":"10.1186/s12964-024-01854-w","DOIUrl":null,"url":null,"abstract":"As the role of RNA modification in gene expression regulation and human diseases, the \"epitranscriptome\" has been shown to be an important player in regulating many physiological and pathological processes. Meanwhile, the phenomenon of cancer drug resistance is becoming more and more frequent, especially in the case of cancer chemotherapy resistance. In recent years, research on relationship between post-transcriptional modification and cancer including drug resistance has become a hot topic, especially the methylation of the sixth nitrogen site of RNA adenosine-m6A (N6-methyladenosine). m6A modification is the most common post-transcriptional modification of eukaryotic mRNA, accounting for 80% of RNA methylation modifications. At the same time, several other modifications of RNA, such as N1-methyladenosine (m1A), 5-methylcytosine (m5C), 3-methylcytosine (m3C), pseudouridine (Ψ) and N7-methylguanosine (m7G) have also been demonstrated to be involved in cancer and drug resistance. This review mainly discusses the research progress of RNA modifications in the field of cancer and drug resistance and targeting of m6A regulators by small molecule modulators, providing reference for future study and development of combination therapy to reverse cancer drug resistance.","PeriodicalId":55268,"journal":{"name":"Cell Communication and Signaling","volume":"22 1","pages":"513"},"PeriodicalIF":8.2000,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11492518/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell Communication and Signaling","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1186/s12964-024-01854-w","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

As the role of RNA modification in gene expression regulation and human diseases, the "epitranscriptome" has been shown to be an important player in regulating many physiological and pathological processes. Meanwhile, the phenomenon of cancer drug resistance is becoming more and more frequent, especially in the case of cancer chemotherapy resistance. In recent years, research on relationship between post-transcriptional modification and cancer including drug resistance has become a hot topic, especially the methylation of the sixth nitrogen site of RNA adenosine-m⁶A (N6-methyladenosine). m⁶A modification is the most common post-transcriptional modification of eukaryotic mRNA, accounting for 80% of RNA methylation modifications. At the same time, several other modifications of RNA, such as N1-methyladenosine (m¹A), 5-methylcytosine (m⁵C), 3-methylcytosine (m³C), pseudouridine (Ψ) and N7-methylguanosine (m⁷G) have also been demonstrated to be involved in cancer and drug resistance. This review mainly discusses the research progress of RNA modifications in the field of cancer and drug resistance and targeting of m⁶A regulators by small molecule modulators, providing reference for future study and development of combination therapy to reverse cancer drug resistance.

查看原文本刊更多论文

解码表观转录组：癌症治疗和抗药性的新领域。

由于 RNA 修饰在基因表达调控和人类疾病中的作用，"表观转录组 "已被证明是调控许多生理和病理过程的重要角色。与此同时，癌症耐药现象日益频繁，尤其是癌症化疗耐药。近年来，转录后修饰与癌症（包括耐药性）之间关系的研究成为热点，尤其是 RNA 第六个氮位点腺苷-m6A（N6-甲基腺苷）的甲基化。与此同时，其他一些 RNA 甲基化修饰，如 N1-甲基腺苷（m1A）、5-甲基胞嘧啶（m5C）、3-甲基胞嘧啶（m3C）、假尿苷（Ψ）和 N7-甲基鸟苷（m7G）也被证实与癌症和耐药性有关。这篇综述主要讨论了 RNA 修饰在癌症和耐药性领域的研究进展，以及小分子调节剂靶向 m6A 调节剂的情况，为今后研究和开发逆转癌症耐药性的联合疗法提供参考。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cell Communication and Signaling CELL BIOLOGY-

CiteScore

11.00

自引率

0.00%

发文量

180

期刊介绍： Cell Communication and Signaling (CCS) is a peer-reviewed, open-access scientific journal that focuses on cellular signaling pathways in both normal and pathological conditions. It publishes original research, reviews, and commentaries, welcoming studies that utilize molecular, morphological, biochemical, structural, and cell biology approaches. CCS also encourages interdisciplinary work and innovative models, including in silico, in vitro, and in vivo approaches, to facilitate investigations of cell signaling pathways, networks, and behavior. Starting from January 2019, CCS is proud to announce its affiliation with the International Cell Death Society. The journal now encourages submissions covering all aspects of cell death, including apoptotic and non-apoptotic mechanisms, cell death in model systems, autophagy, clearance of dying cells, and the immunological and pathological consequences of dying cells in the tissue microenvironment.